arrow
R

Ronald de Wit

erasmus mc cancer institute
H指数:87
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer

Apa/Enza-short研究临床试验方案:一项全国性随机研究,评估在联合雄激素剥夺疗法的情况下,对转移性低体积去势敏感前列腺癌患者使用雄激素受体信号抑制剂缩短至12个月的治疗持续时间。

2026-03-120
PRE
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

循环肿瘤细胞中的染色体不稳定性与转移性去势抵抗性前列腺癌中的卡巴他赛耐药性

2025-12-220
OA
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
CANCER
IF5.1
2024-10-280
OAAI
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

在接受第二线帕博利珠单抗治疗的尿路上皮癌患者中,先前化疗对疗效的影响:KEYNOTE-045 III期试验的探索性分析

2024-08-220
PREAI
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Pembrolizumab联合enzalutamide治疗转移性去势抵抗性前列腺癌在enzalutamide治疗进展: 2期主题199研究的队列4和5

2024-08-121
PRE
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

畸胎瘤对转移性非精原细胞性生殖细胞癌患者生存概率的影响: IGCCCG更新联盟的结果

2024-05-010
PRE
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
2024-03-017
PRE
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
2024-02-143
OAAI
Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum-based chemotherapy
2023-12-270
OA